Moderna was grouped with vaccine stocks after a suspected plague case, but the report does not link the case to its vaccines. Its positive Phase 3 result and planned Merck launch were reported last week, and the COO return is a staffing update; this story adds no clear change to its outlook.
This does not show the Russian case changing demand for Moderna's products. The report does not link its vaccines to plague. The positive Phase 3 result and planned Merck launch matter, but the story says they were reported last week. It also notes Juan Andres's return as COO, not a new product or trial result. Together, these details do not show a new change in Moderna's business outlook.
Vaxcyte announced a $1 billion raise to fund trials, manufacturing and launch work. The plan also brings new shares, warrants and debt, so the funding and added financing balance here.
Novavax was named among vaccine stocks, but the report gives no company-specific product or trial update. The suspected Russia case alone does not show a change to its business outlook.
Follow Moderna Inc. (MRNA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRNA